Clinical Trial

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Study acronym: VAPOR 2
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2023-01-05; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2025-01-07
Status change: Not Yet Recruiting → Recruiting 2023-03-08
Trial Details
NCT Number NCT05683691
Lead Sponsor Francis Medical Inc.
Conditions Prostate Cancer
Enrollment 400 participants
Start Date 2023-05-16
Primary Completion 2027-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-15